Senesco Expands on Preclinical Multiple Myeloma Findings
Senesco has continued its research in both preclinical animal models andhuman multiple myeloma cell lines, while also studying intravenous delivery ofits therapy. In its previously announced preclinical testing and its recentexpanded studies, the Company has used a combination therapy of its siRNAagainst Factor 5A, as well as a plasmid of the Factor 5A gene encapsulated ina nanoparticle.
Whether the combination therapy was injected intratumorally orsystemically, human multiple myeloma tumors grown subcutaneously in the flanksof immunodeficient mice were reduced by approximately 95% versus tumors inuntreated mice. Additionally, groups of treated mice were studied for up tothree weeks after the last therapeutic injection and in mice whose tumors hadregressed, the tumors did not regenerate.
In human multiple myeloma cell line studies, Senesco determined that itssiRNA may sensitize cells for apoptosis through a reduction in activation ofNFkB, a key inflammatory transcription factor. The siRNA also reduced levelsof ICAM (intracellular adhesion molecule), a binding molecule, which isinvolved in promoting tissue inflammation.
The Company, together with its clinical research organization, isevaluating potential manufacturing centers for its materials, planningpreclinical toxicology studies and continuing preclinical disease modelstudies.
About Senesco Technologies, Inc.
Senesco Technologies, Inc. is a U.S. biotechnology company, headquarteredin New Brunswick, NJ. Senesco has initiated preclinical research to trigger ordelay cell death in mammals (apoptosis) to determine if the technology isapplicable in human medicine. Accelerating apoptosis may have applications todevelopment of cancer treatments. Delaying apoptosis may have applications tocertain inflammatory and ischemic diseases. Senesco takes its name from thescientific term for the aging of plant cells: senescence. Delaying cellbreakdown in plants extends freshness after harvesting, while increasing cropyields, plant size and resistance to environmental stress. The Companybelieves that its technology can be used to develop superior strains of cropswithout any modification other than delaying natural plant senescence.Senesco has partnered with leading-edge companies engaged in agriculturalbiotechnology and earns research and development fees for applying itsgene-regulating platform technology to enhance its partners' products.
Certain statements included in this press release are forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Actual results could differ materially from such statementsexpressed or implied herein as a result of a variety of factors, including,but not limited to: the development of the Company's gene technology; theapproval of the Company's patent applications; the successful implementationof the Company's research and development programs and joint ventures; thesuccess of the Company's license agreements; the acceptance by the market ofthe Company's products; success of the Company's preliminary studies andpreclinical research; competition and the timing of projects and trends infuture operating performance, our ability to maintain our continued listingstandards for the next 12 months, as well as other factors expressed from timeto time in the Company's periodic filings with the Securities and ExchangeCommission (the "SEC"). As a result, this press release should be read inconj
You May Also Like